Skip to content
DataLookout
Menu

NCT07504588

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 15 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 22 → 27 locations
  2. Minor Study sites: 27 to 28
  3. Minor Study sites: 23 to 27
  4. Minor Trial sites expanded: 19 → 22 locations
  5. Minor Study sites: 21 to 22
  6. Minor Study sites: 19 to 21
  7. Minor Trial sites expanded: 12 → 19 locations
  8. Minor Trial sites expanded: 9 → 12 locations
  9. Minor Study sites: 10 to 12
  10. Minor Study sites: 9 to 10
  11. Minor Study sites: 7 to 9
  12. Minor Trial sites expanded: 4 → 7 locations
    • Trial sites expanded: 1 → 4 locations
    • Start date changed from estimate of Jun 1, 2027 to Sep 24, 2026
  13. Minor Study sites: 1 to 4
  14. Notable Recruitment opened Show 6 more changesShow less
    • Start date: Sep 10, 2026 to Jun 1, 2027
    • Eligibility criteria expanded, about 11 words
    • Interventions modified
    • Study sites: 0 to 1
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 30 words
  15. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival
Timeframe: From randomization to either progressive disease or death from any cause, assessed up to 5 years

Secondary (4)

Objective response rate (ORR)
Duration of response (DOR)
Incidence of adverse events
Overall survival

Arms and interventions

Arm I (carboplatin, PLD, bevacizumab)Active comparator

Patients receive carboplatin IV on day 1, PLD IV on day 1 (or gemcitabine IV on days 1 and 8), and bevacizumab (or anti-VEGF antibody biosimilar) IV on days 1 and 15 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA at screening and undergo CT and/or MRI and collection of blood samples throughout the trial.

Arm II (SG, bevacizumab)Experimental

Patients receive SG IV over 1-3 hours on days 1 and 8 and bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.

Biologicals: Anti-VEGF Monoclonal Antibody, Bevacizumab, Sacituzumab Govitecan

Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan

Drugs: Carboplatin, Gemcitabine, Pegylated Liposomal Doxorubicin Hydrochloride

Sites

29 sites in 1 country